Aug. 2 Clinical Quick Takes: AB Sciences halts metastatic melanoma program; plus NIH, Adaptimmune and more

AB Sciences drops masitinib for melanoma
AB Science S.A. (Euronext:AB) halted development of masitinib for metastatic melanoma despite reporting that the product led to a 33.3% overall response rate (ORR), the primary endpoint in the Phase III AB08026